THRV-1268 for Atrial Fibrillation

Overseen By Alexandre Brkovic, PhD

Age: 18 - 65

Sex: Any

Trial Phase: Phase 1

Sponsor: Thryv Therapeutics, Inc.

Must not be taking: Immunosuppressants, St. John's wort

Disqualifiers: Pregnancy, Hypertension, Heart disease, others

Compensation: Varies

Number of Visits: 8

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new treatment called THRV-1268 for atrial fibrillation, a heart condition that causes irregular and often rapid heartbeats. Researchers aim to understand how this treatment works in the body, including any effects food might have on it, by comparing it to a placebo (a substance with no therapeutic effect). The trial uses different groups to test both single and multiple doses. Healthy individuals with no significant medical conditions might be a good fit for this trial. As a Phase 1 trial, participants could be among the first to receive this new treatment and help researchers understand its effects in people.

Do I need to stop taking my current medications for the trial?

Yes, you will need to stop taking any prescription drugs (except for hormonal contraceptives or hormone replacement therapy) 28 days before the first study drug administration. Over-the-counter or nutritional supplements should be stopped 7 days before the first study drug administration.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research has shown that THRV-1268 was tested in earlier studies and found to be well-tolerated. In one study with obese adults, participants took single doses of THRV-1268 without significant negative effects, suggesting that THRV-1268 is generally safe for humans. However, since the current trial is in the early phase, it primarily focuses on understanding safety and determining the correct dosage. So far, no major reports of serious side effects have emerged. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising for atrial fibrillation?

Researchers are excited about THRV-1268 for atrial fibrillation because it could offer a novel approach compared to standard treatments like beta-blockers, calcium channel blockers, and anticoagulants. Unlike these treatments that primarily manage symptoms or prevent complications, THRV-1268 may target the underlying mechanisms of atrial fibrillation directly. This new drug could potentially offer more precise control over irregular heartbeats with fewer side effects. Additionally, the inclusion of both single and multiple ascending dose arms, along with a food effect study, allows for a comprehensive understanding of how THRV-1268 behaves in the body, which is crucial for its potential as a new treatment option.

What evidence suggests that THRV-1268 might be an effective treatment for atrial fibrillation?

This trial will evaluate THRV-1268 for atrial fibrillation, a type of irregular heartbeat. Research has shown no evidence yet that THRV-1268 is effective in treating atrial fibrillation. So far, studies have assessed the drug's safety and how the body processes it, but not its efficacy for this heart condition. Trials have found the drug to be safe, which is a positive sign. However, its effectiveness for atrial fibrillation remains unknown. This treatment is in the early research stages, and further studies are needed to determine its potential effectiveness for this condition. ^{1 2 3 4 6}

Are You a Good Fit for This Trial?

This trial is for individuals with atrial fibrillation, a heart condition causing irregular heartbeat. Participants will be screened within 28 days before joining the study to ensure they meet specific health requirements.

Inclusion Criteria

Stated willingness to comply with all study procedures and availability for the duration of the study

I am using birth control, am postmenopausal, or have been surgically sterilized.

I have not smoked or have quit smoking for at least 6 months.

Exclusion Criteria

I am currently breastfeeding.

Abnormal ECG findings

Pregnant females

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

4 weeks

Single Ascending Dose (SAD)

Participants receive a single oral dose of THRV-1268 or placebo, with a food effect arm integrated into one cohort

1 day

1 visit (in-person)

Multiple Ascending Dose (MAD)

Participants receive THRV-1268 or placebo daily from Day 1 to Day 7

1 week

7 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

2 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Placebo
• THRV-1268

Trial Overview

The study tests THRV-1268 against a placebo in two parts: one where participants take a single dose and another where they take multiple doses. The effects of food on the drug are also being studied.

How Is the Trial Designed?

Group I: Single Ascending Dose (SAD) THRV-1268 Experimental Treatment 1 Intervention

5 dosing cohorts will receive a single oral dose of THRV-1268. The highest dose of THRV-1268 to be administered is 500 mg.

Group II: Multiple Ascending Dose (MAD) THRV-1268 Experimental Treatment 1 Intervention

3 dosing cohorts will receive THRV-1268 in the morning on Day 1 to Day 7.

Group III: Food Effect THRV-1268 Experimental Treatment 1 Intervention

food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

Group IV: Single Ascending Dose (SAD) Placebo Placebo Group 1 Intervention

5 dosing cohorts will receive a single oral dose of placebo.

Group V: Food Effect Placebo Placebo Group 1 Intervention

Food effect will be integrated into one of the SAD cohorts as a single dose, two-period with at least a 7-day washout, crossover cohort.

Group VI: Multiple Ascending Dose (MAD) Placebo Placebo Group 1 Intervention

3 dosing cohorts will receive placebo in the morning from Day 1 to Day 7.

Who Is Running the Clinical Trial?

Thryv Therapeutics, Inc.

Lead Sponsor

Trials

3

Recruited

150+

Published Research Related to This Trial

The study found no strong evidence supporting the use of ACE inhibitors or ARBs as effective treatments for preventing or managing atrial fibrillation (AF).

Despite the lack of solid evidence for their antiarrhythmic effects, ACE inhibitors and ARBs may still be beneficial for patients with recurrent AF, especially if they have other conditions like hypertension, heart failure, or diabetes, due to their low side effect profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The role of the renin angiotensin system blocking in the management of atrial fibrillation. Soran, H., Ziglam, H., Al-Najjar, M., et al.[2017]

Patients with atrial fibrillation (AF) undergoing transfemoral aortic valve replacement (TAVR) experienced significantly higher rates of early safety issues and all-cause mortality compared to those in sinus rhythm, with 20.6% of AF patients facing mortality or stroke within 12 months.

Among AF patients, those treated with apixaban had a significantly lower rate of early safety events compared to those on vitamin K antagonists (VKAs), suggesting that apixaban may be a safer anticoagulant option post-TAVR.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. Seeger, J., Gonska, B., Rodewald, C., et al.[2018]

A systematic review of 11 randomized clinical trials involving 56,308 patients found that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduced the relative risk of developing atrial fibrillation (AF) by 28%.

The greatest benefit was observed in patients with heart failure, where the risk of AF was reduced by 44%, while no significant reduction was noted in patients with hypertension, except for those with left ventricular hypertrophy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. Healey, JS., Baranchuk, A., Crystal, E., et al.[2023]

BAY 94-9027, an extended-half-life recombinant factor VIII product, demonstrated a significantly higher pharmacokinetic profile compared to rFVIIIFc, with a higher area under the curve (AUClast) indicating better drug exposure in patients with hemophilia A.

The study, involving 18 patients aged 18-65, found no adverse events, suggesting that BAY 94-9027 is safe for use, and it also showed a longer time to reach FVIII threshold levels, which may benefit patients needing sustained factor levels.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Shah, A., Solms, A., Wiegmann, S., et al.[2023]

A study involving 67 laboratories across 25 countries found that most clinical labs accurately measured the activity of N8-GP (turoctocog alfa pegol) and rAHF (Advate®) using their routine FVIII activity assays, ensuring effective monitoring of hemophilia A treatment.

However, three specific silica-based aPTT reagents significantly underestimated N8-GP levels, recovering only 40%-83% of the target concentration, highlighting the need for careful selection of reagents in clinical settings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A field study evaluating the activity of N8-GP in spiked plasma samples at clinical haemostasis laboratories. Tiefenbacher, S., Clausen, WHO., Hansen, M., et al.[2021]

The Phase 3 A-LONG study showed that rFVIIIFc is highly effective for treating acute bleeding episodes in severe hemophilia A, with 98% of episodes resolving after one or two infusions.

Among subjects receiving prophylactic treatment, a significant number (60% in individualized prophylaxis) did not experience target joint bleeds, highlighting the potential of rFVIIIFc to prevent bleeding complications.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Treatment of bleeding episodes with recombinant factor VIII Fc fusion protein in A-LONG study subjects with severe haemophilia A. Shapiro, AD., Mahlangu, JN., Perry, D., et al.[2017]

Candesartan significantly reduces the atrial fibrillatory rate in patients with high baseline rates (>420 fibrillations/min), indicating its potential anti-arrhythmic effects in atrial fibrillation.

Despite reducing the fibrillatory rate, candesartan did not improve the success of cardioversion outcomes, suggesting that lower fibrillatory rates (<360 fpm) are more critical for successful cardioversion rather than the drug's effects.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Fibrillatory rate response to candesartan in persistent atrial fibrillation. Bollmann, A., Tveit, A., Husser, D., et al.[2021]

A meta-analysis of 26 randomized controlled trials found that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) significantly reduce the risk of developing atrial fibrillation (AF), with an overall odds ratio of 0.65, indicating a strong preventive effect.

The preventive effects were particularly pronounced for recurrent AF (odds ratio of 0.45) compared to new-onset AF (odds ratio of 0.80), and were most effective in patients already treated with amiodarone, suggesting a synergistic benefit.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The role of renin-angiotensin system blockade therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials. Zhang, Y., Zhang, P., Mu, Y., et al.[2022]

A systematic analysis of 6226 reports of atrial fibrillation (AF) related to COVID-19 vaccines showed that AF is a rare adverse event, accounting for only 0.3% of all vaccine-related reports in the European pharmacovigilance database from 2020 to November 2022.

Most AF cases were reported in adults over 65 years old, with 35% requiring hospitalization and 10% being life-threatening, although the majority of AF events were of short duration (median = 24 hours).

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database. Ruggiero, R., Donniacuo, M., Mascolo, A., et al.[2023]

In a study of 160 patients with recent atrial fibrillation, oral doses of flecainide, amiodarone, and propafenone were all significantly more effective than placebo in converting patients to sinus rhythm within 24 hours, with conversion rates of 87.5%, 85%, and 85% respectively compared to only 17.5% for placebo.

Flecainide and propafenone showed quicker conversion rates within 3 hours (57.5% and 45% respectively), while amiodarone was more effective between 6 and 24 hours, indicating that different antiarrhythmic drugs may have varying onset times for effectiveness.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacological conversion of recent atrial fibrillation: a randomized, placebo-controlled study of three antiarrhythmic drugs. Balla, I., Petrela, E., Kondili, A.[2013]

BAY 81-8973 demonstrated effective bleed prevention and treatment in previously untreated or minimally treated patients with severe hemophilia A, with a median annualized bleeding rate of 0.0 within 48 hours after prophylaxis infusion among patients without inhibitors.

While the study observed a higher than expected rate of inhibitors (39.5% high titer), immune tolerance induction was successful in 50% of patients who underwent treatment, indicating that BAY 81-8973 maintains a favorable benefit-risk profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial. Ljung, R., Chan, AKC., Glosli, H., et al.[2023]

In a network meta-analysis of 39 studies involving 27,766 patients, continuous vitamin K antagonist (C-VKA) was found to significantly reduce thromboembolic events and major bleeding complications compared to interrupted vitamin K antagonist (I-VKA) in patients undergoing radiofrequency catheter ablation for atrial fibrillation.

Rivaroxaban was identified as the most effective and safest non-vitamin K oral anticoagulant, showing a lower risk of thromboembolism compared to I-VKA, making it a strong alternative to C-VKA for these patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation. Li, PJ., Xiao, J., Yang, Q., et al.[2018]

In a study involving 212 patients with severe hemophilia A, full-length sucrose-formulated recombinant factor VIII (rFVIII-FS) demonstrated high efficacy, successfully treating 85.4% of bleeding episodes with one or two infusions.

The long-term safety profile of rFVIII-FS was confirmed, with a low incidence of inhibitor formation (8.0% in previously untreated patients), supporting its use in clinical practice for up to 24 months.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting. Musso, R., Santagostino, E., Faradji, A., et al.[2018]

A systematic review of 21 trials involving 91,381 patients found that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) reduced the incidence of atrial fibrillation (AF) by 25%.

The effectiveness of ACEIs/ARBs was particularly notable in patients with hypertension, chronic heart failure, and those already diagnosed with AF, showing a relative risk reduction of 24% for primary prevention and 27% for secondary prevention.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers decrease the incidence of atrial fibrillation: a meta-analysis. Huang, G., Xu, JB., Liu, JX., et al.[2011]

Citations

1.

thryvtrx.com

thryvtrx.com/news/1268-ind-esc-2025-results

Thryv Therapeutics Receives FDA IND Clearance of THRV ...

A Phase 1 study (NCT06507839) evaluating the safety, tolerability and pharmacokinetics of THRV-1268 demonstrated that the compound was well- ...

2.

clinicaltrials.gov

clinicaltrials.gov/study/NCT07186946

NCT07186946 | Phase 1, Single Ascending Dose Study to ...

Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, PK, PD, and Comparative Bioavailability of THRV-1268 in Obese Adult Participants.

3.

prnewswire.com

prnewswire.com/news-releases/thryv-therapeutics-receives-fda-ind-clearance-of-thrv-1268-for-clinical-programs-in-heart-failure-and-atrial-fibrillation-and-presents-results-of-sgk1-inhibition-combined-with-jardiance-empagliflozin-an-sglt2-inhibitor-in-a-pr-302548339.html

Thryv Therapeutics Receives FDA IND Clearance of THRV ...

A Phase 1 study (NCT06507839) evaluating the safety, tolerability and pharmacokinetics of THRV-1268 demonstrated that the compound was well- ...

4.

withpower.com

withpower.com/trial/phase-1-atrial-fibrillation-5-2024-e2dc6

THRV-1268 for Atrial Fibrillation · Info for Participants

The available research does not provide any data supporting the effectiveness of THRV-1268 for Atrial Fibrillation. The studies mentioned focus on ...

5.

admarebio.com

admarebio.com/en/news-details/thryv-therapeutics-receives-fda-ind-clearance-of-thrv-1268-for-qt-syndrom

Thryv Therapeutics Announces FDA IND Clearance of ...

The primary endpoint is the mean change from baseline in area under the curve corrected QT interval (QTc AUC (0-6)/6) over six weeks of ...

6.

ctv.veeva.com

ctv.veeva.com/study/study-to-assess-the-safety-tolerability-pharmacokinetic-of-thrv1268

Study to Assess the Safety, Tolerability, Pharmacokinetic of ...

5 dosing cohorts will receive a single oral dose of THRV-1268. The highest dose of THRV-1268 to be administered is 500 mg. Treatment: Drug: THRV ...